Medistim

Board approval of the 2024 Financial statements for Medistim ASA

(Oslo, 8th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader

within ultrasound technology with headquarter in Norway, that develops and

commercializes medical equipment for use within cardiac, vascular and transplant

surgery, announces that the Board of Medistim ASA has approved the Financial

Statements for 2024. The Financial Statements are without changes from the

preliminary Financial Statements published on the 28th of February 2025. The

annual report for 2024 is now available. The Annual General Meeting will be held

on 8th of May 2025.

About Medistim:

Medistim was established in 1984, and has a track record of profitable growth

over the past >15 years. The company is a pioneer within its segment and

continues to invest in new product development. Medistim has wholly owned

subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,

Canada, China, Sweden and Norway, in addition to the about 60 distributors in

Europe, Asia, Middle East, Africa, and South America. For more information,

visit the Medistim home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

AI Terminal